Home > Healthcare > Biotechnology > Bioservices > Adeno Associated Virus Vectors Manufacturing Market

Adeno Associated Virus Vectors Manufacturing Market Share

Report ID: GMI6876
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Adeno Associated Virus Vectors Manufacturing Market Share

In the realm of AAV vector manufacturing, several notable companies have established themselves as key players, each contributing to the dynamic landscape of gene therapy. Lonza, Thermo Fisher Scientific and Catalent, Inc are prominent entity in this sector, offers an extensive array of services encompassing process development, manufacturing, and analytical testing for AAV vectors. These companies, along with numerous others, collectively contribute to the advancement and growth of the AAV vector manufacturing market, underlining their critical role in the evolution of gene therapy and its potential to transform the landscape of medical treatments.

Market players operating in adeno associated virus vectors manufacturing is as mentioned below:

F. Hoffmann-La Roche (Spark Therapeutics)
Biomarin Pharmaceutical
Oxford BioMedica plc
WuXi AppTec
YPOSKESI
Sarepta Therapeutics
Regenxbio Inc.
Audentes Therapeutics
4D Molecular Therapeutics
Ultragenyx Pharmaceutical Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global adeno associated virus vectors manufacturing industry value was USD 769.7 million in 2022 and will surpass USD 6.1 billion by 2032, attributed to expanding pipeline of gene therapy, advancements in vector production technology, and increased diversification of therapeutic areas.

The neurological disorders segment is anticipated to witness a growth rate of 22.3% between 2023 – 2032 as AAV vectors play a pivotal role in delivering therapeutic genes to specific cells within the nervous system, and they can either integrate into the host genome or persist as episomal structures, offering prolonged therapeutic benefits.

North America AAV vector manufacturing market is slated to reach USD 3 billion by end of 2032, owing to the region’s significant involvement in the clinical trials and commercialization of gene therapy products, many of which harness the potential of AAV vectors.

F. Hoffmann-La Roche (Spark Therapeutics), Biomarin Pharmaceutical, Oxford BioMedica plc, WuXi AppTec, YPOSKESI, Sarepta Therapeutics, Regenxbio Inc., Audentes Therapeutics, and 4D Molecular Therapeutics among others.